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Abstract
This discussion article examines narrative positioning related to pain management for people who use
substances at the end of life. We explore how dominant narrative genres associated with biomedicine, such
as ‘restitution’ and narratives common within the context of drug services such as ‘recovery’ can hinder
effective pain management within this population. We argue that these discourses can marginalise the
ethical self-identity of patients who use substances at the end of life. It can also trouble health and social
care professionals in supporting patients and generating counter-narratives that challenge those often
associated with substance use. Stigma is a common experience for this population with stereotyping as
‘junkies’ and associated with criminality. They are positioned as drug-seeking, and this requires more
surveillance at the end of life when opioid therapy is potentially more available and authorised. This can
make it challenging to generate ‘companion’ stories that are positive and maintain moral adequacy.
Dominant biomedical narrative genres often prevent the recognition of the fractured stories that people
using substances can often present with. This can lead to narrative silencing and to the under treatment of
pain. The person’s self-identity is invested in narratives of recovery, and opioid use symbolises their
addicted past because for practitioners, this population is at clinical risk with the potential for drug
seeking behaviours. Whilst not requiring formal ethical review this discussion paper was constructed in
accordance with good scientific practice with the work of other researchers respected and cited
appropriately.
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Introduction
This article seeks to explore the context of pain management at the end of life for people who use
substances. These reflections are based on a wider unique project funded by (National Lottery Community
Fund) examining end-of-life care for people who use substances.1 This theoretical exploration stems from
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data generated from five strands of the project which included a rapid evidence assessment (REA),2 inter-
views with individuals with palliative care needs who use substances.3 Interviews were also conducted to
explore family, carer and friends’ experiences of people using substances at the end of life,4 to examine
practitioners’ perspectives5 and to gain key informant insights into the issues pertinent to this population.6
We examine the dominant narrative genres that frame the stories related to pain management and substance
use and how this delineates and defines the ethical landscape. We argue that the narrative positioning of
‘recovery’ remains unhelpful within the context of end-of-life care with implications both for health and
social care professionals and people who use substances. We contextualise these data through a narrative
approach7–11 highlighting how constructions such as ‘recovery’ narratives can unhelpfully define the
frames of reference for appropriate responses to people using substances at the end of life.
We all generate our narrative lives through different elements or fragments of the available cultural
repertoire.11 Stories therefore become either good or bad companions and as adapted, collected and (re)in-
terpreted they become material semiotic companions. Stories are never unique but are collected, more like
‘reassembled fragments on loan’11 that retain the genesis of standard character, plot and style in a recog-
nised schema. Within biomedical narratives, the dominant or canonical biomedical genres,10 grand narra-
tives or master narratives12 do not convey single unified stories but often present as ensembles of repeated
themes. These themes can become oppressive, particularly in this case, focusing on recovery or restitution
within a population that is nearing the end of life. If a patient is unable to present a coherent, recognisable
narrative (e.g. through lack of social capital or because of stigmatising attributes), then they are more open
to narrative silencing.11 How well a person is able to present a counter-narrative,12 for example, not to be
cast as a ‘junkie’, can be challenging, particularly being able to present new less oppressive ‘companion’
stories which support rather than stigmatise them.
Background
In the last two decades, there has been an increase in older drug users and a subsequent rise in rates of death
from non-drug-related conditions.13 This increase means that current and previous substance users now
survive long enough to die of conditions more commonly found in deprived cohorts of the wider popula-
tion.14 Furthermore, changes in life expectancy in the general population are leading to a pattern of
population ageing which is likely to be mirrored in the smaller population of substance users. This means
predictive end-of-life care is needed since this population is not just dying due to acute overdose but rather
other chronic conditions such as cancer, heart or respiratory disease.
Pain management within the context of people using substances can be challenging, and within acute
clinical settings, it can be suboptimal or non-existent.15,16 Stigma is likely to exacerbate the problems for
this population, particularly if using Goffman’s17 definition as an ‘an attribute that is deeply discrediting’.
For example, popular media representation of people using substances as ‘junkies’ based on prolific heroin
use and criminality.18 Patients are drug seeking rather than having ‘legitimate’ reasons for opioid-based
pain medication. Specifically, stigma theory developed by Earnshaw and Chaudoir19 suggests that struc-
tural and social stigma, associated with substance use, is experienced by individuals as enacted, anticipated,
and internalised.1 For a number of people using heroin, the treatment regime itself became stigmatising and
set people up to expect more stigma from other parts of the health and social care system.18 Radcliffe and
Stevens18 referred to segregation in pharmacies and the supervised consumption of medication as a humi-
liation and thus monitoring at the end of life reinforces their ‘Junkie’ status. This stigma associated with
substance use can lead to diagnostic overshadowing20 where health professionals, in this case, attribute
behaviours to substance dependency rather than to the pain associated with end-of-life conditions. This can
lead to poor pain management at the end of life for people with problematic substance use.21 We interpret
stigma as affecting different levels of social life, and Pescosolido et al.’s22 framework is helpful in focusing
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on the micro or psychological level factors, the meso or social network level factors and macro or societal
wide factors. Examining all these aspects also moves the narrative away from the individualisation of health
and examines wider health (in)equality. For example, Imtiaz et al.23 notes that in the United States crude
mortality rates of drug- and alcohol-induced causes of death have increased but is disproportionately borne
in lower socio-economic strata and throughout high-income countries there are extreme health inequalities
across a range of health conditions.24
Pain management is one of the pivotal priorities in effective palliative care. There is a general consensus
within the evidence base that the most pressing problem in relation to substance misuse is not the phenom-
enon itself. Rather, it is the continual under treatment of pain in this population at the end of life, driven by
the unexplored concerns related to opioids misuse.25–30 Levels of prescribing may need to be higher for
people using substances because of their tolerance to opioids from historic drug use. This may contravene
established clinical guidelines in terms of opioid titration.
Farnham28 describes how uncertain prescribers may withholdmedication and appropriate doses. There is
also a fear of overdose and drug diversion of prescribed medications within this population group.30,31
Templeton et al.,6 for example, found there was a clear acknowledgement by health professionals of this
issue in the approach to pain management quoting,
We talk about the pain . . .what the patient tells you it is but that doesn’t seem to apply to this group in terms of
other people, ‘so they’re looking for drugs, they’ve asked for it four hourly’, whereas if it was a wee old lady who
was 80 who was asking for extra painkiller, they’d be paging us going, ‘She’s really sore, you need to come and
do something about it.
Some literature recognises that psychiatric co-morbidities can lead to ‘chemical coping’ strategies. This
is defined in this literature as the potential for patients with a history of substance use to access illicit drugs
in an attempt to control unmanaged pain. Authors also mentioned ‘pseudo-addiction’; behaviours that are
misunderstood by health and social care staff as drug seeking (when patients ‘act out’ when distressed),
rather than originating from poor or inadequate pain control.25 There has been a challenge in using the label
of ‘pseudo-addiction’ on both grounds of limited evidence and a logical inconsistency since people with a
history of substance use cannot have a pseudo-addition as it is part of their history and therefore this label is
not applicable.32 Some papers30 also delineated a need to distinguish between tolerance, physical depen-
dence, and addiction, although they did not specify how this can be achieved.
Narrative positioning and substance use
Differing narrative approaches can be adopted and taken up by both patients and practitioners. How they
position themselves to these companion stories has important implications and impacts on approaches to
pain management for practitioners and people using substances at the end of life. Narrative approaches
provide a lens to examine narrative positioning and draw out the dominant discourses that may impact care
practices in this population. We argue that more dominant narrative genres can minimise and marginalise
the experiences of patients, making it more challenging for practitioners to respond effectively to the
complexity of people using substances at the end of life. It can also affect the self-identity of the patient
in managing the consequences of stigma. Evidence suggests that these populations are narratively silenced
and more stigmatised than other groups.33,34 Frank35 refers to the predominant narrative within medicine as
linked to restitution in that medical interventions are designed to restore the patient back to their previous
good health. When patients present with a more chronic and fractured, ‘chaos’ narrative then this becomes
more challenging for them and practitioners to recognise a coherent story and makes them more likely to
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misread the stories generated. This chaos narrative can often characterise the presentation of those patients
using substances.
Often within biomedical genres, narratives precede and authorise medical interventions, with the official
story subsuming subsequent developments as either successful or failed technical procedures. Being a good
practitioner means being able to construct narratives that persuade others of an ordered reality requiring
identifiable effective actions.36 Hence, someone using substances at the end of life may present with
multiple confounding variables that could affect standard protocols for pain management. They present
with a ‘chaos’ narrative35 that is perceived to need quantifying and medical assessment in order to assess
risk. Frank37 highlights a protocol-driven system that fails to examine the cultural frame in which it is heard.
If the answer to a question does not fit with the practitioners expectations then patients could face difficulty
getting the care needed. These ‘canonical biomedical genres’10 carry moral imperatives. It is an ethical
requirement to identify, assess and address aberrant drug seeking behaviour. If the person using substances
at the end of life takes up this narrative construction it becomes an ethical imperative to abstain from illicit
drug use and avoid opioid use, even at the end of life, since it is perceived to be associated with ethical
inadequacy and a moral failure to strive for a narrative of recovery. The internalisation of these narratives
can inflict a kind of systemic oppression on their self-identities, and it derives from taking up unhelpful
narrative genres that can be damaging to identity construction.
Mattingly10 asserts that healing narratives associated with biomedicine provide ‘an authorized action
framework’10 in order to interpret both the narrative ground and expectations of how these healing dramas
should unfold. In the enactment of this narrative structure, other ‘facts’ or voices that do not coherently fulfil
the narrative construct are silenced. This may be exacerbated by culturally endorsed stereotypes of sub-
stance users being associated with criminality and other stigmatised health conditions such as HIV disease,
mental illness or hepatitis C.38 There is also evidence to suggest that people using substances are likely to be
perceived as having personal control over these problems and subsequently more liable to be blamed and
held responsible for the consequences of these actions.39,40 This is reflected in health professional attitudes
with Boekel et al.41 suggesting they perceive substance users to be violent, manipulative, and poorly
motivated, leading to a task-orientated approach to care delivery with limited empathetic engagement by
staff. Galvani et al.5 also found a clear acknowledgement of this issue by health professionals in approach-
ing pain management, the assumption being that patients with a history of using substances often exhibit
drug-seeking behaviours. These dominant or ‘master’ narratives12 are often archetypal, constituting recog-
nisable plots, schemas and stories, for example, the manipulative drug user who will fake symptoms to get
opioids. Such oppressive master narratives also cause doxastic damage in distorting self-image and self-
identity of the person using substances.38 They also involve a recognisable repertoire of character types that
do not form single unified stories but often present as ensembles of repeated themes. In terms of metho-
dological approach, we examined data that related to pain management from the REA.2 This was a major
theme generated from the REA through textual narrative synthesis.42 From the remaining strands of the
wider project, we identified data specifically addressing issues of pain management and examined these
data, as a team, in light of the findings of the REA.We examined narrative context to all these data and used
positioning theory43 since this can provide a framework in which performance is enacted with the position-
ing of the self in personal narratives generating self-identity.
Narratives of surveillance and clinical uncertainty
There are clear concerns for practitioners regarding pain management at the end of life for people using
substances. Galvani et al.5 give examples from practice of people who had misused prescribed pain
medication, including one person who had buried illicit drugs in the grounds of the hospice for use when
he went into the gardens; others who sought prescriptions for opiate-based medication from multiple
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sources including the oncologist, general practitioner (GP), and hospital; the misuse of pain patches
including smoking them, dissolving them and sharing them out, and selling on some of their pain medica-
tions. Use and misuse of pain medication by family members or friends was also highlighted as a problem.
These examples highlight the ‘borderlands’44 of clinical encounters when potential marginalisation can take
place. Populations that may not present a coherent, recognisable, culturally appropriate narrative frame, but
rather have a more ‘chaotic’, fractured narrative can be open to cultural misrecognition and stigma.10 This
requires health care professionals to engage in what Mattingly10 describes as ‘narrative mind reading’ in
which they need to explore and acknowledge the complexity of a person’s narrative life and avoid stereo-
typing people using substances, for example, as just someone exhibiting drug seeking behaviour. If health
professionals position people as ‘flat’ characters whose self-narrative becomes an insignificant subtext to
the plot of diagnosis, treatment and recovery, then a person-centred approach to pain management is
difficult to implement and maintain.
Within the literature, pain management is the topic most common to emerge in relation to substance use
at the end of life.2 Within this literature, there appeared conflicting narratives between narratives of
abstinence and risk reduction within substance use at the end of life, with surveillance often offered as a
strategy to monitor safe opioid use. This surveillance was based on a recommendation for universal screen-
ing for substance misuse, urine testing, and sometimes pill counting.25,27,31,45,46 There was an emphasis on
the need to use validated tools.27,31,47 Some papers recommended or used a particular measure to assess
potential opioid misuse.21,26 There is insufficient evidence, however, to confidently support the accuracy or
efficacy of most of these instruments.47 The feasibility, acceptability and clinical impact of these instru-
ments remain uncertain, with instruments potentially too lengthy to realistically administer in most clinical
settings. There is limited generalisability with a lack of evidence relating to evaluation of the impact of these
instruments.46,48,49 Within most biomedical narratives, this surveillance is an ethical requirement often
predicated on risk assessment. The practitioner has to demonstrate professional propriety and moral
accountability even if the evidence suggests these current strategies are ineffectual. This is similar to other
strategies such as urine drug testing, considered a ‘gold standard’ in terms of substance misuse identifica-
tion.46,49 Although it may be helpful in risk identification, there is a lack of evidence to support its accuracy
or effectiveness in predicting, preventing or reducing substance use behaviours in chronic pain patients.49,50
There is a high potential for false negatives or false positives that may compromise diagnostic accuracy and
patient-health professional relationships. Patients could perceive an implicit message within this interaction
that health professionals are not interested in what they say but will only trust test results. There are also
issues of cost-effectiveness and accessibility as well as difficulty interpreting the results.
The desire to maintain moral adequacy with ineffectual surveillance strategies is not often problematized
by practitioners. Surveillance becomes part of narrative silencing by narrowing the focus of interest to a set
of guidelines to manage pain rather than an opportunity to engage with the narrative complexity often
affecting this population at the end of life. This is not to suggest that there are no genuine concerns of safety
and vulnerability, such as the potential for opioid diversion–whether relating to either the patient selling, or
their family/friend using or selling, prescribed opiates. There are limited, evidence based solutions like
limited supply of medication, written opioid agreements or prescription monitoring pro-
grammes.27,28,30,31,51 For example, opioid treatment agreements may, in practice, be discriminatory and
actually intensify stigma. They may also be implemented inequitably.52,53 Rather than seeking protocols
that stereotype people using substances and lack robust evidence and evaluation applying a more person-
centred approach would seem a more appropriate approach. Narratives that stigmatise people using sub-
stances can have significant consequences in end-of-life care. For example, there is evidence that hospice
staff have concerns about insufficient access to anticipatory end-of-life medications and under-prescribing
for this group of patients from GPs who are concerned about drug misuse as Galvani et al.5 comment,
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I think sometimes I’ve had an issue where GPs . . . have been reluctant to put end of life anticipatory medications
in if they know there’s been a history or there’s some people in the family that have got problems with drug
use . . . I think, generally speaking, there’s a huge ignorance in managing pain in patients who are either current
drug users or past drug users at end of life with cancer. There is a fear isn’t there about prescribing?
Talking about substance use
There are a number of issues of concern in relation to pain management, substance use and communication.
From a narrative approach, people make sense and interpret their lives through stories, justifying and
positioning themselves. It constitutes and grounds identity formation and therefore exploring the underlying
concerns through a narrative approach can potentially identify some of the wider cultural context in which
these positions are (re)framed. Underpinning most of the current literature on pain management and end-of-
life care was the prerequisite to effectively and often directly communicate with this population.27,28,51
Whether this happened, how to achieve it and what sort of strategies would be helpful in managing direct
conversations about substance misuse was not a feature of the current literature. Talk, Taylor54 reminds us,
is the site and range of practices in which our identities are constituted out of the cultural narrative resources
available. ‘Thus identities are in part conferred through positioning and in part actively constituted, con-
tested and negotiated by active speakers’ (p. 99).54 If health professionals need to distinguish between active
users, individuals in methadone replacement therapy, and those in recovery,30 then narrative complexity
requires narrative intelligence. An awareness of the companion stories that may help or hinder a person in
constructing their self-identity. These require comprehensive, open and non-judgemental negotiations that
many general health professionals may feel ill equipped to undertake. This is particularly challenging when
many health professionals interpret risk in terms of their personal safety and feel incompetent in approach-
ing this population.55 This issue is highlighted by Galvani et al.5 who quotes a hospice health professional:
I know that I struggled with thinking about the drugs and what to suggest prescribing. I mean if some-
body’s on so much Diazepam that they’re taking, you know, what do you then do in terms of symptom
management? How do you manage their anxiety when they’re already taking shed loads of Diazepam?
For people using substances and their families, the world of clinical encounters can generate unfamiliar
languages, rituals and expectations about how to act their part. Moreover, as Radcliffe and Stevens’18
accounts of enacted stigmatisation in treatment and accessing prescriptions reveals, people using substances
and their families may well be anticipating similarly stigmatising attitudes from all health practitioners and
so adopt quite defensive positions. People using substances may present a fractured narrative unfamiliar to
clinicians or as Mattingly10 comments; worse still, they may appear as ‘familiar strangers’, prejudged and
slotted in categories where they are dismissed, invisible, neither known nor deemed worth knowing.
Some patients appear to be concerned that their level of substance use will preclude them from having
pain and symptommanagement at high enough levels.5,6 Their competence and ability to present a narrative
frame that maintains moral adequacy is often compromised. In this sense, maintaining moral adequacy and
accounting for the ethical self is a critical element within any narrative.8 This aspect is further articulated,
not just in assumptions about drug-seeking behaviour but in that some people will resist or refuse some
medications (e.g. opioids) because of their history of substance use.6 They have worked hard onmaintaining
a narrative of recovery, of restitution, and these medications represent a failure in this process. Effective
communication in examining and working with these narratives to support patients with substance use
problems at the end of life is an important element of a person-centred approach.
Communication about the goals of care and substance use is also significant with some patients not being
able to, or wanting to, stop using for a range of reasons, including unresolved underlying issues such as
experiences of abuse or trauma. This complexity cannot be reduced by biomedical narrative canons to a
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problem focused ‘puzzle’ for the practitioner to solve using their clinical expertise10 with minimal input
from the person themselves. Life experiences of people using substances have generated storied resources
that both enable and constrain a speakers’ identity work. Working with people to explore the meanings
attached to the narratives presented can support patients who require a clear realistic assessment of the
narrative context of care. Patients, for example, exposed to narratives that stigmatise people using sub-
stances may stockpile medications or not give an accurate baseline of illicit drug use for fear of under-
treatment.6
Pain management, social networks and narrative diversity
People live in networks rather than isolated from the social context of life and these form integral parts of
people’s narratives. This is often not acknowledged within formalised healthcare,56 and there is a need to
recognise the impact and importance of families and peers, and whether they can positively support the
person using substances at the end of life.4,6 This is particularly important since the context related to family
and peers may, in this population, be detrimental to good pain management (with potential risk of people
stealing or diverting medicines) or be positive–given the dearth and inaccessibility of effective social care
for disenfranchised populations. The context of managing end-of-life care for people using substances is
an important issue and the identification of significant others in the person’s life can facilitate safe and
meaningful care at the end of life. Templeton et al.6 gives an example of how one narrative included a pub
landlady looking after the medication for one isolated pub regular. She was his designated next of kin,
kept the anticipatory end-of-life medications and looked out for his safety – noting if he did not come into
the pub. For those who were homeless, it was sometimes a shelter worker or a friend at a hostel who was
closest to the person and could potentially assist with medication, but this required proactive engagement
from health and social care staff to facilitate this.57 Radden and Fordge56 challenge the ideology of
individualism prevalent with biomedical narratives that can isolate and define the subject in a way that
compounds social isolation:
Consistency suggests that what was begun by others should be continued by them. And this point would not so
readily be lost from sight were the distorting ideology of individualism which casts each person the master of
their fate and captain of their soul to be replaced with more realistic, collectivist assumptions-as it surely
should be.
Within pain management at the end of life, one of the primary health professional goals is to assess,
titrate and monitor a patient in terms of safe doses of opioid and adjuvant medications for symptom control.
Substance use can make this goal challenging without fully engaging with the complex fractured narratives
that some patients can present with. These narratives often include a set of ‘characters’ who are not often
recognised and acknowledged by health professionals, as in the examples above. The plot becomes that of a
‘troublesome familiar stranger’,9 a ‘drug abuser’ presented as acting in predictable but unreasonable,
unaccountable and possibly immoral ways. It therefore becomes ethically legitimate to monitor family,
and to assess support workers and peers for signs of medication misuse. Without being open to narrative
diversity, the stories and characters that have significance for the patient are minimised.
Caught between conflicting narratives
A challenge to the management of pain and symptoms can be the differing views and approach of profes-
sionals between abstinence and risk reduction, from narratives that stigmatise people using substances and
those that are more inclusive and supporting. The existence of stigma would suggest some encounters with
health professionals could be more judgemental and task-orientated in approach compared to a more
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empathetic approach from others, and this can make it difficult for patients using substances to know what
to expect and perhaps anticipate the worse. Narrative constructions can have a direct clinical impact, for
example, Galvani et al.5 indicate some health and social care professionals were not worried that cancer
patients may become dependent on opioids and that there should be no difference when talking to patients
using substances about the right titration of medication for them. One area, however, where there appeared
to be conflicting opinion between health and social care professionals was related to whether a patient
should be asked or told to stop their own substance use in order to receive medication for pain and
symptoms, particularly opioid medication.6 Some staff felt every vial of morphine should be accounted
for while others felt that counting medications was meaningless in the face of imminent death. This can
cause difficulties with substance use treatment services who often advocate for abstinence, presenting a
narrative of recovery.58,59 This can make managing pain at the end of life challenging from both the
reluctance of health professionals to prescribe or give appropriate doses of opioids and from patient who
is in recovery and does not want to risk psychological and physical burdens associated with addiction.
Instances where people with histories of substance use refused opiate-based medication even at the end of
their lives are challenging.6 As Galvani et al.5 quotes one hospice professional:
I’ve come across the opposite, where people with a drug problem in the past are so reluctant to consider
painkillers again because they’re so fearful, . . . I do have another lady on my caseload just now, who is an ex
user. And interestingly, she really will not take it. She won’t take the liquid morphine, she’s terrified of taking it.
She’ll try and put up with the pain, because of that fear of addiction.
However, Templeton et al.6 describes family members’ experiences of relatives who had a history of
drug use but now abstinent, reaching the end of life. The family often insisted that medical staff did not
prescribe opioids for as long as possible since the person in recovery did not want the associated problems
they experienced with addiction. The utility of recovery when someone is approaching end of life is
questionable. The ‘recovery’ narrative, in this context, silences other stories and reduces the available
narratives, for example, a ‘good death’ based on effective symptom management. As Frank11 would
suggest, the companion stories that could be taken up and positioned by people using substances are
silenced by, in this case, a grand narrative of recovery. Without this effective counter-story, identities are
marginalised and silences are distilled within narrative foreclosure.
Conclusion
Effective pain management for end-of-life care for people using substances can be challenging for a number
of reasons. Health professionals often feel that they lack the expertise and confidence to manage pain
requiring higher opioid titration that may exceed standard prescribing protocols for end-of-life care. This
requires creative thinking and an acknowledgement that pain is more than a physiological response, with
this population potentially experiencing significant previous trauma that can affect emotional and psycho-
logical distress at the end of life. This requires narrative intelligence that ultimately opens up the storied
lives of patients using substances in a way that engages with the meaning(s) that we attach to the disease
process that confronts us. This is significant because it can affect how we manage and approach symptoms
of pain at the end of life. This needs relationship building and effective communication rather a formulaic,
protocol driven pain management process. There is a wider issue with narrative ethics that is important to
articulate which centres on narrative privilege: whose narrative is excluded or silenced? Stories can be good
or bad companions. Some companion stories can be helpful, so stories of drug recovery, of renewed ‘self-
recovery’ founded on the principles of abstinence can be a significantly supportive narrative in the lives of
someone using substances. There also needs to be an acknowledgement that narratives related to abstinence
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may actively discourage people using substances from seeking adequate pain relief at the end of life since
this may be associated with a ‘chaos’ that they have worked hard to overcome. For these reasons, narrative
intelligence and effective multi-agency working is not only important, it is an ethical imperative to support
pain management in this marginalised population at the end of life.
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